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Statement of findings
The kinetics of apoptosis and the apoptosis-regulating gene p53 in adjuvant arthritis (AA)
were investigated to assess the value of the AA rat model for testing apoptosis-inducing
therapies. Very few terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate (dUTP) nick end-labeling (TUNEL)-positive cells were detected during the early
phases of AA, but on day 23 (chronic arthritis) the percentage of TUNEL-positive cells was
significantly increased. Expression of p53 in synovial tissue gradually increased from days
5–23, which was markedly higher than p53 levels in rheumatoid arthritis (RA) synovium.
Significant apoptosis only occurs late in rat AA and is concordant with marked p53
overexpression, making it a useful model for testing proapoptotic therapies, but rat AA is not
the best model for p53 gene therapy because dramatic p53 overexpression occurs in the
latter stages of the disease.
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AA = adjuvant arthritis; dUTP = deoxyuridine triphosphate; RA = rheumatoid arthritis; TUNEL = terminal deoxynucleotidyl transferase-mediated
dUTP nick end-labeling.
Introduction: RA is a chronic inflammatory disorder that is
characterized by inflammation and proliferation of synovial tissue.
The amount of DNA fragmentation is significantly increased in
rheumatoid synovium. Only low numbers of apoptotic cells are
present in rheumatoid synovial tissue, however. The proportion of
cells with DNA strand breaks is so great that this disparity
suggests impaired apoptosis. Therefore, the development of
novel therapeutic strategies that are aimed at inducing apoptosis
in rheumatoid synovial tissue is an attractive goal.
Although animal models for arthritis only approximate RA, they
provide a useful test system for the evaluation of apoptosis-
inducing therapies. AA in rats is among the most commonly
used animal models for RA. For the interpretation of such
studies, it is essential to characterize the extent to which
apoptosis occurs during the natural course of the disease.
Therefore, we evaluated the number of apoptotic cells and the
expression of p53 in various phases of AA.
Materials and methods: In order to generate the AA rat
model, Lewis rats were immunized with Mycobacterium
tuberculosis in mineral oil on day 0. Paw swelling usually
started around day 10. For the temporal analysis rats were
sacrificed on days 0, 5 (prearthritis), 11 (onset of arthritis), 17
(accelerating arthritis), or 23 (chronic arthritis).
For the detection of apoptotic cells, the hind paws were
harvested on days 0 (n = 6), 5 (n = 6), 11 (n = 6), 17 (n = 6), or
23 (n = 4). The right ankle joints were fixed in formalin,
decalcified in ethylenediaminetetra-acetic acid, embedded in
paraffin, and sectioned. The TUNEL method was applied. The
percentage of TUNEL-positive cells of the total inflammatory
cell infiltrate was noted.
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For Western blot analysis, hind paws were harvested on days 0
(n = 2), 5 (n = 3), 11 (n = 4), 17 (n = 4), or 23 (n = 4). In
addition, hind paws of normal rats (n = 2) were studied. The
right ankle joints were snap frozen and pulverized. Synovial
tissue was also obtained by arthroscopy of three patients with
longstanding (>5 years) RA. After protein extraction in lysis
buffer, equal amounts of protein samples from lysates were
pooled and examined by Western blot analysis using anti-p53
monoclonal antibody DO7, which recognizes wild-type and
mutant p53 from rodents and humans.
For immunohistochemical analysis, six rats were sacrificed on
day 23 after immunization and synovial tissue of the right ankle
joints was snap frozen and evaluated by immunohistochemistry
using anti-p53-pan. The sections were evaluated semi-
quantitatively using a 0–4 scale.
The Kruskal–Wallis test for several group means was used to
compare the percentage of TUNEL-positive cells at different
time points.
Results: The percentages of TUNEL-positive cells were
strongly dependent on the stage of the disease. Very few
TUNEL-positive cells were detected in normal rats or in the early
phases of AA; the number of TUNEL-positive cells was 1% or
less of the total cell infiltrate, including neutrophils, from days
0–17 (Table 1). On day 23, however, the percentage of TUNEL-
positive cells was significantly increased [15.8±5.1% (mean
±standard error of the mean); P=0.01]. TUNEL-positive cells
were observed in the intimal lining layer and synovial sublining of
the invasive front, as well as in the articular cartilage (Fig. 1).
Subsequently, we examined expression of the tumor
suppressor gene p53, because this is a key regulator of
apoptosis. Expression of p53 in pooled rat AA joint extracts
gradually increased from day 0 (6 arbitrary units) to day 23
(173 arbitrary units), which was markedly higher than p53
levels in RA synovium (32 arbitrary units; Table 1).
Overexpression of p53 protein on day 23 was confirmed by
immunohistochemistry in a separate experiment in six rats with
AA. Overexpression of p53 was observed in the intimal lining
layer and synovial sublining in all rats on day 23. In all cases a
semiquantitative score of 4 was assigned, indicating that 51%
or more of the cells were positive, whereas control sections
were negative.
Discussion: The results presented here reveal that the number
of TUNEL-positive cells remained very low until chronic arthritis
developed. This indicates that, although there was sufficient
Figure 1
(Left) Swelling of the left hind paws (mean ± standard error of the mean) in different phases of adjuvant arthritis (AA). Swelling usually starts
around day 10 after immunization, followed by the development of accelerating arthritis (day 17) and chronic arthritis (day 23). (Right) Distribution
of TUNEL-positive cells (red, indicated by arrows) in joints of AA rats on day 11 (a and c) and on day 23 (b and d). Very few TUNEL-positive cells
were detected in normal rats or during the onset of arthritis, whereas the number of number of TUNEL-positive cells was significantly increased in
the synovium (and also in cartilage) of rats with chronic AA. TUNEL method counterstained with Mayer’s hemalum. Original magnification 250×.
Table 1
Percentages of TUNEL-positive cells and p53 expression in
synovial tissue of rats with adjuvant arthritis in different
phases of the disease
Expression of p53
Day TUNEL-positive cells (%) (arbitrary units)
0 0.2 ± 0.2 6
5 0.3 ± 0.2 13
11 0.5 ± 0.2 98
17 1.0 ± 0.0 153
23 15.8 ± 5.1 173
Values are expressed as mean ± standard error of the mean
percentages of TUNEL-positive cells in synovial tissue, or as p53
expression in pooled samples of rat joints in arbitrary units.
http://arthritis-research.com/content/2/3/229
Introduction
RA is a chronic inflammatory disorder that is characterized
by inflammation and proliferation of synovial tissue. The
disease is still associated with long-term morbidity and
early mortality, despite treatment with antirheumatic drugs.
Inadequate apoptosis appears to contribute toward pro-
longed survival and constitutive activation of specialized
cells in rheumatoid synovium [1,2]. The amount of DNA
fragmentation is significantly increased in rheumatoid syn-
ovium [3,4], which is presumably due to the toxic environ-
ment of the chronically inflamed joint [5]. Only low
numbers of apoptotic cells are present in rheumatoid syn-
ovial tissue, however [4,6–8]. The proportion of cells with
DNA strand breaks is so great that this disparity suggests
impaired apoptosis. The observation that mice with the
lymphoproliferative or generalized lymphoproliferative dis-
order, which have mutations that inactivate Fas and Fas
ligand, respectively, develop pathology similar to that
observed in immune-mediated diseases [9,10] illustrates
that reduced apoptosis may play an important role in the
pathogenesis of synovitis.
The p53 tumor suppressor is a key regulator of DNA
repair and cell replication [11]. DNA damage activates
p53, thereby inducing cell growth arrest to allow time for
DNA repair. When DNA damage is extensive the cells may
undergo apoptosis. Inactivation of the p53 gene renders
cells less susceptible to undergo apoptosis [12]. The p53
system ensures that cells with damaged DNA either die or
are repaired. We have previously proposed that impaired
apoptosis in rheumatoid synovial tissue might be explained
in part by the development of permanent genetic changes
in the p53 tumor suppressor gene [5,13]. In addition,
other factors may be involved, such as protection against
apoptosis by nuclear factor-κB activation [14–16], a rela-
tive deficiency of functional Fas ligand in the RA joint [17],
and expression of antiapoptotic molecules, such as bcl-2
[3] and sentrin [18]. Therefore, the development of novel
therapeutic strategies aimed at inducing apoptosis in
rheumatoid synovial tissue is an attractive goal.
Although animal models of arthritis only approximate RA,
they provide a useful test system for the evaluation of
apoptosis-inducing therapies. AA in rats is among the
most commonly used animal models for RA [19,20]. This
model has recently been used to investigate the effects of
bisindolylmaleimide, a compound that facilitates Fas-medi-
ated apoptosis [21]. Rat AA might also provide a useful
screening model for the evaluation of gene therapies that
are aimed at induction of apoptosis, because the size of
the joints permits relatively easy intra-articular injection
[22]. For the interpretation of such studies, however, it is
essential to characterize the extent to which apoptosis
occurs during the natural course of the disease. Therefore,
we evaluated the number of apoptotic cells and the
expression of p53 in various phases of AA.
Materials and methods
Adjuvant arthritis model
Male Lewis rats (150–200 g) were immunized at the base
of the tail with 1 mg Mycobacterium tuberculosis H37 RA
(Difco, Detroit, MI, USA) in 0.1 ml mineral oil on day 0
[23]. Paw swelling usually started around day 10. For the
temporal analyses, rats were killed on days 0, 5 (prearthri-
tis), 11 (onset of arthritis), 17 (accelarating arthritis), or 23
(chronic arthritis) by carbon dioxide narcosis. All animals
Full article
DNA damage to cause an increment in p53 expression in the
early phases, DNA strand breaks that can be detected by
TUNEL assays only occurred in chronic AA. The observation
that TUNEL-positive cells were nearly absent in early AA clearly
indicates that only very few cells were undergoing programmed
cell death. This is an important observation, which makes it
possible to study the effects of apoptosis-inducing therapies in
situ in early and accelerating AA. An effective therapy would
obviously increase the number of TUNEL-positive cells.
There is already some overexpression of p53 in the preclinical
phase and during the onset of the arthritis, with an additional
increment in p53 expression during accelarating and chronic
arthritis. Presumably, this is wild-type p53, because the disease
duration is likely too short to allow for the development of p53
mutations. Transcription of p53 is probably increased in
response to the toxic environment of the inflamed joint. The
increased expression of p53 in the joints of rats with chronic
AA was even greater than that observed in synovial tissue of
RA patients with long-standing disease.
Overexpression of p53 and increased numbers of apoptotic
cells did not occur simultaneously in this model; rather p53
overexpression preceded increased apoptosis. Activation of
p53 leads to induction of cell growth arrest, allowing time for
DNA repair. It appears that DNA damage is only extensive
enough to induce apoptosis in the latter stages of AA. Factors
other than p53 may also play an important role in the actual
induction of apoptosis.
Taken together, significant apoptosis only occurs late in AA
and it follows marked p53 overexpression, making it a useful
model for testing proapoptotic therapies. AA is not the best
model for p53 gene therapy, however, because dramatic p53
overexpression occurs in the latter stages of the disease.
were handled in accordance with Uuniversity of California
San Diego Animal Subjects Committee and United States
Department of Agriculture guidelines.
Detection of apoptotic cells
The hind paws were harvested on days 0 (n = 6), 5 (n = 6),
11 (n = 6), 17 (n = 6), or 23 (n = 4). The right ankle joints
were fixed in formalin, decalcified for 4 weeks in 15%
ethylenediaminetetra-acetic acid in phosphate-buffered
saline, embedded in paraffin, and sectioned. For detection
of apoptotic cells the TUNEL method was applied, based
on terminal deoxynucleotidyl transferase-mediated labeling
of free 3′-hydroxy termini exposed in cells that exhibit DNA
strand breaks. An in situ cell death detection alkaline
phosphatase kit from Boehringer Mannheim (Indianapolis,
IN, USA) was used according to the manufacturer’s
instructions. For detection of alkaline phosphatase activity
we used the alkaline phosphatase substrate kit I (Fast
Red) from Vector Laboratories (Burlingame, CA, USA).
The percentage of TUNEL-positive cells of the total inflam-
matory cell infiltrate was noted.
Western blot analysis
Hind paws were harvested on days 0 (n=2), 5 (n=3), 11
(n=4), 17 (n=4), or 23 (n=4). In addition, hind paws of
normal rats (n=2) were studied. After removal of skin and
muscle tissue, the right ankle joints were snap frozen in
liquid nitrogen and pulverized. Synovial tissue was also
obtained by arthroscopy of three patients with longstanding
(>5 years) rheumatoid factor-positive, erosive RA; these
patients have been described previously [24]. All patients
had active arthritis in a knee joint and elevated serum levels
of C-reactive protein. The patients were treated with nons-
teroidal anti-inflammatory drugs. None were treated with
corticosteroids or immunosuppressive drugs, such as aza-
thioprine, methotrexate, or cyclophophamide, within 3
months before study entry [24]. After protein extraction in
lysis buffer, equal amounts of protein samples (in total
20µg/lane) from lysates were pooled and run on a gel in
order to normalize for differences in synovial cellularity [24].
The pooled samples were then transferred onto a nitrocellu-
lose membrane, and p53 protein detected with 0.25 µg/ml
of the Immunoglobulin G2b mouse anti-p53 monoclonal anti-
body DO7 (Novocastra Laboratories Ltd, Newcastle, UK),
which recognizes wild-type and mutant p53 from rodents
and humans. After incubation with horseradish peroxidase-
conjugated goat-antimouse antibody, horseradish peroxi-
dase activity was detected using hydrogen peroxide as the
substrate and visualized by chemiluminescence. Densitome-
try was performed with Image software version 1.57
(National Institutes of Health, Bethesda, MD, USA). Results
are expressed as arbitrary densitometry units.
Immunohistochemistry
Six rats were sacrificed on day 23 after immunization, and
synovial tissue of the right ankle joints was snap frozen in
Tissue-Tek OCT (Miles Diagnostics, Elkhart, IN, USA) by
immersion in methylbutane (–70°C). All slides were
stained in one procedure. Endogenous peroxidase activity
was inhibited using 0.1% sodium azide and 0.3% hydro-
gen peroxide in phosphate-buffered saline for 30 min. The
biotinylated anti-p53-pan (Boehringer Mannheim) was
diluted to a final concentration of 2 µg/ml and incubated
for 60 min. In negative control sections the primary anti-
body was omitted or irrelevant antibody was applied at the
same concentration as the primary antibody. This was fol-
lowed by incubation with avidin–biotin–peroxidase
complex (Vectastain ABC Kit; Vector Laboratories),
biotinylated tyramine, and horseradish peroxidase-conju-
gated streptavidin, as previously described [24]. Horse-
radish peroxidase activity was detected using hydrogen
peroxide as substrate and 3,3′-diaminobenzidine (DAB;
Vector Laboratories) as dye. Sections were coded and
randomly analyzed [24]. The sections were evaluated
semiquantitatively using a 0–4 scale as follows: 0, no
staining; 1, rare positive staining or trace staining (1–5%);
2, scattered clusters of positive cells (6–15%); 3, moder-
ate staining in a specific region (16–50%); and 4, exten-
sive staining throughout a region (51–100%) [24].
Statistical analysis
The Kruskal–Wallis test for several group means was
used to compare the percentage of TUNEL-positive cells
at different time points.
Results
Apoptosis in different phases of adjuvant arthritis
Detection of apoptotic cells was performed on the basis of
in situ labeling of DNA strand breaks. Representative
examples of the TUNEL stainings in relation to the paw
volumes in various phases of the disease are shown in
Figure 1. The percentages of TUNEL-positive cells were
strongly dependent on the stage of the disease. Very few
TUNEL-positive cells were detected in normal rats or
during the early phases of AA; the number of TUNEL-posi-
tive cells was 1% or less of the total cell infiltrate, including
neutrophils, from days 0–17 (Table 1). On day 23,
however, the percentage of TUNEL-positive cells was sig-
nificantly increased (15.8±5.1% [mean±standard error of
the mean]; P=0.01). TUNEL-positive cells were observed
in the intimal lining layer and synovial sublining of the inva-
sive front as well as in the articular cartilage (Fig. 1).
Expression of p53 in different phases of adjuvant arthritis
Subsequently, we examined expression of the tumor sup-
pressor gene p53, because this is a key regulator of apop-
tosis. Expression of p53 in pooled rat AA joint extracts
gradually increased from day 0 (6 arbitrary units) to day 23
(173 arbitrary units), which was markedly higher than p53
levels in RA synovium (32 arbitrary units; Table 1 and
Fig. 2). Overexpression of p53 protein on day 23 was con-
firmed by immunohistochemistry in a separate experiment
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in six rats with AA. Overexpression of p53 was observed
in the intimal lining layer and synovial sublining in all rats
on day 23 (Fig. 3). In all cases a semiquantitative score of
4 was assigned, indicating that 51% or more of the cells
were positive, whereas control sections were negative.
Discussion
Rat AA is a T-cell dependent disease, which is character-
ized by paw swelling, joint erosions and ankylosis, as well
as systemic manifestations. Infiltration of the synovium by
leukocytes precedes the development of clinical signs and
symptoms of arthritis [25,26]. There is also an increase in
the numbers of CD8+ T cells and B cells in the regional
lymph nodes in the preclinical phase [27]. As shown in the
present study, clinical signs of arthritis usually appear by
days 10–12. Subsequently, paw volume markedly
increases as a result of cellular infiltration and edema of
synovial tissue [28].
The results presented here reveal that the number of
TUNEL-positive cells remained very low until chronic
arthritis developed. Severe disease and marked paw
swelling characterize this phase. The results indicate that,
although there was sufficient DNA damage to cause an
increment in p53 expression in the early phases, DNA
strand breaks that can be detected by TUNEL assays only
occurred in chronic AA. In general, the results may be
false positive, because TUNEL-positive cells are not nec-
essarily apoptotic [2]. The observation that TUNEL-posi-
tive cells were nearly absent in early AA, however, clearly
indicates that only very few cells were undergoing pro-
grammed cell death. We have recently shown that there is
increased oxidative stress in chronic arthritis [29], which
may play a pivotal role in the induction of DNA strand
breaks [5]. The results in the AA model suggest that the
production of reactive oxygen and nitrogen species is not
sufficiently increased in the earliest phases of arthritis to
lead to induction of apoptosis. This is an important obser-
vation, which makes it possible to study the effects of
apoptosis-inducing therapies in situ in early and accelerat-
ing AA. An effective therapy would obviously increase the
number of TUNEL-positive cells.
There is already some overexpression of p53 in the pre-
clinical phase and during the onset of the arthritis, with an
additional increment in p53 expression during accelerating
and chronic arthritis. Presumably, this is wild-type p53,
http://arthritis-research.com/content/2/3/229
Figure 2
Western blot analysis showing immunoreactive p53 in pooled joint
extracts of rats with AA and pooled synovial tissue samples of patients
with RA. Expression of p53 gradually increased from days 0–23 in rat
AA (see also Table 1). Overexpression on day 23 (173 arbitrary units)
was markedly higher than p53 levels in RA synovium (32 arbitrary
units).
Figure 3
Representative synovial tissue from a rat with adjuvant arthritis on day
23, showing marked p53 overexpression [(a), indicated by arrows].
Both cytoplasmic and nuclear staining was noted in the intimal lining
layer (L) and in the synovial sublining (S). Staining was absent in the
negative control section (b). Monostaining peroxidase technique with
tyramine enhancement counterstained with Mayer’s hemalum. Original
magnification 400×.
because the disease duration is probably too short to
allow for the development of p53 mutations. Transcription
of p53 is probably increased in response to the toxic envi-
ronment of the inflamed joint, with local production of
oxygen radicals, nitric oxide [30], and cytokines. Similarly,
exposure of human fibroblasts to nitric oxide generated
from a nitric oxide donor or from overexpression of
inducible nitric oxide synthase may result in accumulation
of wild-type p53 [31]. There are also several examples of
overexpression of wild-type p53 in human inflammatory
diseases, which include the following: inflammation in ath-
erosclerotic plaques [32], idiopathic pulmonary fibrosis
[33], Helicobacter pylori-associated gastritis [34,35],
ulcerative colitis [36], Crohn’s disease [36], chronic pan-
creatitis [37], infectious colitis [38], lymphocytic thyroiditis
[39], and RA [1,24,40,41]. The increased expression of
p53 in the joints of rats with chronic AA was even greater
than that observed in synovial tissue of RA patients with
long-standing disease. Because there is already dramatic
p53 overexpression in the latter stages of the disease, AA
is probably not the best model to evaluate p53 gene
therapy. Indeed, we could achieve only a marginal addi-
tional increase in p53 expression by in vivo gene transfer
(unpublished data).
Overexpression of p53 and increased numbers of apop-
totic cells did not occur simultaneously in this model;
rather p53 overexpression preceded increased apoptosis.
Activation of p53 leads to induction of cell growth arrest,
allowing time for DNA repair. It appears that DNA damage
is only extensive enough to induce apoptosis in the latter
stages of AA. Factors other than p53 may also play an
important role in the actual induction of apoptosis, such as
tumor necrosis factor-α, interactions between Fas and Fas
ligand, and degranulation of granules that contain
granzymes and perforin.
Taken together, significant apoptosis only occurs late in
AA and it follows marked p53 overexpression, making it a
useful model for testing proapoptotic therapies. AA is not
the best model for p53 gene therapy, however, because
dramatic p53 overexpression occurs in the latter stages of
the disease.
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